Home › Therapeutic areas › Neurology › Multiple Sclerosis
Multiple Sclerosis (15 companies)
Companies with an active program in Multiple Sclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $341M | 12 |
| CLNN | Clene | Neurology Rare | 1 | NDA Submitted | $56.9M | 5 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $374M | 4 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 1 | Approved | $1.94B | 17 |
| IMUX | Immunic | GI/HepatologyNeurology | 2 | Phase 3 | $106M | 4 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 1 | Phase 3 | $417M | 5 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $296M | 5 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $5.4M | 7 |
| TGTX | Tg Therapeutics | Neurology Rare | 3 | Approved | $9.16B | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $87.8M | 5 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 3 | NDA Submitted | $1.92B | 11 |
No companies match.